Think

Search This Blog

Trump’s Testimonial Is a Double-Edged Sword for Regeneron

October 09, 2020

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

BY KATIE THOMAS AND DENISE GRADY via NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?

BY EMILY ANTHES | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

A new drug slashes deaths among patients with severe Covid, the drug’s developer claims.

BY RONI CARYN RABIN | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

Powered by Blogger

Trump’s Testimonial Is a Double-Edged Sword for Regeneron

Comments

Post a Comment